MigVax-101
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Oral

MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]

References

  1. ↑ Jaffe-Hoffman M (11 June 2021). "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. Retrieved 2 November 2021.
  2. ↑ Jaffe-Hoffman M (22 July 2021). "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. Retrieved 2 November 2021.
  3. ↑ "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. Retrieved 2 November 2021.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.